Evidence map›Paper›PMID 28331814›Full record

ReviewBiomolecular detection and quantification2017

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Mary Alikian, Robert Peter Gale, Jane F Apperley, Letizia Foroni

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecular detection and quantification, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 49 citations in OpenAlex.

  1. The silent players: AtypicalOncology reports · 2025
    Review
  2. The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025
    Review
  3. Article
  4. Review
  5. A customized mass array panel forJournal of mass spectrometry and advances in the clinical lab · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Digital PCR forHemaSphere · 2020
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mary AlikianCentre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK; Imperial Molecular Pathology, Imperial College Healthcare Trust, Hammersmith Hospital, London, UK.
Robert Peter GaleCentre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK.
Jane F ApperleyCentre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK.
Letizia ForoniCentre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK.
Imperial College London · GBHammersmith Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on the reduction of blood or bone marrow

Indexed as

ABL1, Abelson murine leukaemia virusALL, acute lymphoblastic leukaemiaallo-SCT, Allogeneic Stem Cell TransplantationAP, accelerated phaseARQ, armored RNA QuantATP, adenosine triphosphateBC, blast crisisBCR, breakpoint cluster regionBM, bone marrowBMT, bone marrow transplantationBp, base pairCAP, College of American PathologycDNA, coding or complimentary DNACES, capillary electrophoresis sequencingCMLCML, chronic myeloid leukaemiaCMR, complete molecular response/remissionCP, chronic phaseDESTINY, De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiadMIQE, Minimum Information for Publication of Quantitative Digital PCR ExperimentsDNA, deoxyribonucleic aciddPCRdPCR, digital polymerase chain reactionEAC, Europe Against CancerELN, European Leukaemia NetemPCR, emulsion PCREURO-SKI, European Stop Tyrosine Kinase Inhibitor StudygDNA, genomic deoxyribonucleic acidGUSB, glucuronidase beta geneIC, inhibotory concentrationInDels, insertions and deletionsIRIS, interferon and cytarabine versus STI571IS, International ScaleKbp, Kilo Base PairsKDa, Kilo DaltonLoD, limit of detectionLoQ, limit of quantificationLPC, leukemic progenitor cellsLSC, leukemic stem cellM-bcr, major-breakpoint cluster regionm-bcr, minor-breakpoint cluster regionMbp, mega base pairMMR, major molecular response/remissionMolecular monitoringMRDMR, deep molecular response/remissionMRD, minimal residual diseasemRNA, messenger RNANCCN, National Comprehensive Cancer NetworkNEQAS, National External Quality Assessement ServiceNGSNGS, next generation sequencingnM, manomolarNTC, No Template ControlPB, Peripheral BloodPCR, Polymerase Chain ReactionPFS, Progression Free SurvivalPh, PhiladelpiaQC, Quality ControlQ-PCR, quantitative polymerase chain reactionRT-dPCR, reverse transcription-digital polymerase chain reactionRT-qPCR, reverse transcription-quantitative polymerase chain reactionRT, reverse transcriptionSCT, stem cell transplantSMRT, single-molecule real-time sequencingSTIM, stop imatinibTKD, tyrosine kinase domainTKI, tyrosine kinase inhibitorWHO, World Health OrganisationZMW, zero-mode wave-guidedμ-bcr, micro-breakpoint cluster regionμg, microgramμl, microliter

Identifiers

PMID28331814
PMCPMC5348117
OpenAlexW2588846711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.